Abstract
AstraZeneca is to co-promote Abbott’s Trilipix® (fenofibric acid) for the treatment of lipid disorders, which will increase the exposure of Trilipix in the cholesterol market. The two companies filed an NDA for the combination of Trilipix with Crestor® (rosuvastatin), known as Certriad®.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
